Intra-Cellular Therapies (NASDAQ:ITCI) is set to issue its quarterly earnings data before the market opens on Thursday, February 25th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.
NASDAQ ITCI opened at $38.97 on Tuesday. The firm has a market cap of $3.12 billion, a PE ratio of -12.10 and a beta of 1.50. Intra-Cellular Therapies has a one year low of $10.94 and a one year high of $40.01. The stock’s 50 day simple moving average is $34.88 and its 200 day simple moving average is $27.56.
ITCI has been the topic of a number of recent research reports. BTIG Research decreased their price objective on Intra-Cellular Therapies from $80.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, November 2nd. They noted that the move was a valuation call. Bank of America initiated coverage on Intra-Cellular Therapies in a research report on Tuesday, December 15th. They issued a “buy” rating and a $40.00 price objective on the stock. Cantor Fitzgerald increased their price objective on Intra-Cellular Therapies from $53.00 to $54.00 and gave the company an “overweight” rating in a research report on Tuesday, December 29th. Zacks Investment Research lowered Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Wednesday, January 13th. Finally, The Goldman Sachs Group initiated coverage on Intra-Cellular Therapies in a research report on Thursday, December 10th. They issued a “buy” rating and a $38.00 price objective on the stock. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $45.00.
In other news, insider Suresh K. Durgam sold 2,734 shares of the stock in a transaction on Friday, February 19th. The stock was sold at an average price of $39.25, for a total value of $107,309.50. Following the transaction, the insider now owns 25,838 shares of the company’s stock, valued at approximately $1,014,141.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Sharon Mates sold 48,341 shares of the stock in a transaction on Monday, January 4th. The shares were sold at an average price of $31.30, for a total value of $1,513,073.30. In the last three months, insiders sold 202,103 shares of company stock worth $6,746,845. 18.20% of the stock is currently owned by company insiders.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
See Also: How to Use a Moving Average for Trading
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.